Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 781

Sort by

Sort Order Select

Journal Articles

A master erythroid regulator gets its own GPS

Lily Jun-shen Huang, James J. Bieker

Blood (2020) 135 (25): 2209–2210.

https://doi.org/10.1182/blood.2020005882

Published: 2020

Journal Articles

TET1 Modulates DNA Replication in Leukemia Cells Via a Catalytic-Independent Mechanism through Cooperating with KAT8

Hengyou Weng, PhD, Huilin Huang, PhD, He Huang, Zhaojin Yu, Paulina Siejka-Zielinska, Zhenhua Chen, PhD, Emily Prince, Chao Shen, PhD, Zejuan Li, MD, Chunxiao Song, Yingming Zhao, Jianjun Chen, PhD

Blood (2019) 134 (Supplement_1): 1249.

https://doi.org/10.1182/blood-2019-127321

Published: 2019

Journal Articles

Leukemogenic Functions of Mutant ASXL1 Are Regulated By CDK-Mediated Phosphorylation

Shuhei Asada, MD PhD, Susumu Goyama, MD PhD, Reina Takeda, MD, Keita Yamamoto, MD, Hiroko Kozuka-Hata, PhD, Masaaki Oyama, PhD, Daichi Inoue, MD PhD, Hiroaki Honda, MD PhD, Toshio Kitamura, MD PhD

Blood (2019) 134 (Supplement_1): 731.

https://doi.org/10.1182/blood-2019-125959

Published: 2019

Journal Articles

A Novel Composition of Endogenous Metabolic Modulators, AXA4010, Impacts Adhesion, Inflammation and RBC Membrane Deformability in Preclinical Models of Sickle Cell Disease

Michael Hamill, PhD, Sean Carroll, PhD, Revati Wani, PhD, Matthew Russell, PhD, Zoe Steuert, Arianna Nitzel, Andrew Downey, PhD, Murat Cokol, PhD, Raffi Afeyan, PhD, Svetlana Marukian, PhD, Tony Tramontin, PhD

Blood (2019) 134 (Supplement_1): 978.

https://doi.org/10.1182/blood-2019-124224

Published: 2019

Journal Articles

Multiple Myeloma Epigenetic Programming Prognostic of Outcome Converges with Loci Reprogrammed in Relapsed/Refractory Disease

Benjamin G Barwick, PhD, Sheri Skerget, PhD, Jonathan J Keats, PhD, Daniel Auclair, Sagar Lonial, Lawrence H. Boise, PhD, Paula M Vertino, PhD, Doris R Powell, MA

Blood (2019) 134 (Supplement_1): 858.

https://doi.org/10.1182/blood-2019-124422

Published: 2019

Journal Articles

Innate Immune Signaling Suppresses Acute Leukemia By Modifying MYC Oncogenic Activity

Tomoya Muto, MD PhD, Maria Guillamot, PhD, Jing Fang, MD PhD, Luna Zea Redondo, MS, Kwangmin Choi, PhD, Yixiao Gong, MSc, Callum S Walker, MSc, Kathleen Hueneman, Lyndsey C Bolanos, BSc, Laura Barreyro, PhD, Lynn Lee, MD, Kenneth D Greis, PhD, Alireza Khodadadi-Jamayran, M.Sc., Amaia Lujambio, PhD, Scott W. Lowe, PhD, Iannis Aifantis, PhD, Daniel T. Starczynowski, PhD

Blood (2019) 134 (Supplement_1): 727.

https://doi.org/10.1182/blood-2019-121423

Published: 2019

Journal Articles

Mechanistic Basis and Efficacy of Targeting β-Catenin-TCF7L2-JMJD6-MYC Axis to Overcome Resistance to BET Inhibitors

Christopher Peter Mill, PhD BA, Warren Fiskus, BSc,PhD, Dyana T. Saenz, PhD, Bernardo H Lara, Vrajesh Karkhanis, PhD, Taghi Manshouri, PhD, Isean Bhalla, Nancy Shao, James V Maher, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

Blood (2019) 134 (Supplement_1): 538.

https://doi.org/10.1182/blood-2019-125142

Published: 2019

Journal Articles

Myeloid-Lineage Enhancers Drive Oncogene Synergy and Represent a Novel Therapeutic Target in CSF3R-CEBPA Mutant AML

Theodore Braun, MD PhD, Cody Coblentz, Sarah A Carratt, PhD BS, Mariam Okhovat, PhD, Amy Foley, MEng., Zachary Schonrock, BS, Kimberly Nevonen, Rhonda E. Ries, MA, Shannon K. McWeeney, PhD, Claus Nerlov, PhD, Soheil Meshinchi, MD PhD, Lucia Carbone, PhD, Brian J. Druker, Julia E. Maxson, PhD

Blood (2019) 134 (Supplement_1): 543.

https://doi.org/10.1182/blood-2019-124773

Published: 2019

Journal Articles

A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis

Kristen Pettit, MD, Aaron T. Gerds, MD MS, Abdulraheem Yacoub, MD, Justin M. Watts, MD, Maciej Tartaczuch, MD, Terrence J Bradley, MD, Jake Shortt, MBBS FRACP FRCPA PhD, William S. Stevenson, MBBS,PhD, Natasha Joan Curtin, MDFRACP,FRCPA, James M. Rossetti, DO, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Georges Natsoulis, PhD, Amber Jones, MA, Moshe Talpaz, MD, Jennifer Peppe, BS, David M Ross, MD PhD, Hugh Young Rienhoff, Jr., MD

Blood (2019) 134 (Supplement_1): 556.

https://doi.org/10.1182/blood-2019-123244

Published: 2019

Journal Articles

Pre-Clinical Efficacy of Co-Treatment with KDM1A (LSD1) Inhibitor and Ruxolitinib or BET Inhibitor Against Post-MPN-sAML Blast Progenitor Cells

Warren Fiskus, BSc,PhD, Christopher Peter Mill, PhD BA, Vrajesh Karkhanis, PhD, Bernardo H Lara, Prithviraj Bose, MD, Lucia Masarova, Tapan M. Kadia, MD, Nancy Shao, Isean Bhalla, James V Maher, Joseph D. Khoury, MD, Sunil Sharma, MD, Taghi Manshouri, PhD, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

Blood (2019) 134 (Supplement_1): 1274.

https://doi.org/10.1182/blood-2019-130783

Published: 2019

Journal Articles

Nascent Transcript and Single Cell Rnaseq Analysis Defines the Mechanism of Action of the LSD1 Inhibitor INCB059872 in Myeloid Leukemia

Gretchen Johnston, Haley E. Ramsey, PhDMSc, Kristy Stengel, PhD, Shilpa Sampathi, PhD, Pankaj Acharya, PhD, Maria Arrate, MSc, Matthew C. Stubbs, PhD, Timothy Burn, PhD, Scott Hiebert, PhD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 2509.

https://doi.org/10.1182/blood-2019-130458

Published: 2019

Journal Articles

PRMT5 Is a Key Epigenetic Regulator That Promotes Transcriptional Activation in Mantle Cell Lymphoma By Regulating the Lysine Methyltransferase SETD7 and MLL1 Activity

JI Hyun Chung, PhD, Shelby Sloan, BS, Peggy Scherle, PhD, Kris Vaddi, PhD, Said Sif, PhD, Rosa Lapalombella, PhD, Robert A Baiocchi, MD PhD

Blood (2019) 134 (Supplement_1): 2777.

https://doi.org/10.1182/blood-2019-131020

Published: 2019

Journal Articles

SEL120 - a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial

Blood (2019) 134 (Supplement_1): 2651.

https://doi.org/10.1182/blood-2019-127835

Published: 2019

Journal Articles

A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid Leukemia

Kamal Menghrajani, MD, Sheng F Cai, MD PhD, Sean M. Devlin, PhD, Scott A. Armstrong, MD PhD, Richard Piekarz, MD PhD MS, BA, Michelle Rudek, PharmD, PhD, Martin S. Tallman, MD, Eytan M. Stein, MD

Blood (2019) 134 (Supplement_1): 2655.

https://doi.org/10.1182/blood-2019-121926

Published: 2019

Journal Articles

Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures

Blood (2019) 134 (Supplement_1): 1710.

https://doi.org/10.1182/blood-2019-123877

Published: 2019

Journal Articles

Inhibition of LSD1 in Myelodysplastic Syndrome Progenitors Restores Differentiation of CD141 Hi Conventional Dendritic Cells

Pragya Srivastava, PhD, Stephanie Tzetzo, Eduardo Cortes Gomez, Kevin Eng, Prashant K Singh, PhD, Kitty De Jong, Sheila N. J. Sait, PhD, Kyle Wiatrowski, Miranda L Lynch, PhD, Jennifer Peresie, BS, Jianmin Wang, PhD, Elizabeth A. Griffiths, MD, Michael J. Nemeth, PhD

Blood (2019) 134 (Supplement_1): 1695.

https://doi.org/10.1182/blood-2019-126220

Published: 2019

Journal Articles

Myelodysplastic Syndromes-Associated Gene Mutations Lead to Pseudohypoxia Condition and Epigenome Hyper-Methylation in Mouse Genetic Models

Asumi Yokota, PhD, Lulu Zhang, PhD, Jianhua Feng, Xiaomin Feng, MD PhD, Xiaomei Yan, MD PhD, Gang Huang, PhD

Blood (2019) 134 (Supplement_1): 1696.

https://doi.org/10.1182/blood-2019-126799

Published: 2019

Journal Articles

Gck Kinase Activity Is Critical for RAS Mutated Myeloma - a Potential Treatment Approach for Targeting Specific Mutations

Shirong Li, PhD, Jing Fu, PhD, Xiaoming Xu, PhD, Shixian Deng, PhD, Markus Y Mapara, MD PhD, Christophe Marcireau, Suzanne Lentzsch, MD PhD

Blood (2019) 134 (Supplement_1): 1813.

https://doi.org/10.1182/blood-2019-129531

Published: 2019

Journal Articles

Novel Therapeutic Rationale for Targeting HDAC1 and PIM2 in Multiple Myeloma

Takeshi Harada, MD PhD, Asuka Oda, Hiroto Ohguchi, MD PhD, Yohann Grondin, PhD, Hirofumi Tenshin, DDS, PhD, Masahiro Hiasa, DDS, PhD, Jumpei Teramachi, Masahiro Oura, MD, Kimiko Sogabe, MD, Shiro Fujii, MD PhD, Shingen Nakamura, MD PhD, Hirokazu Miki, MD PhD, Kumiko Kagawa, MD PhD, Shuji Ozaki, MD PhD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD, Masahiro Abe, MD PhD

Blood (2019) 134 (Supplement_1): 3111.

https://doi.org/10.1182/blood-2019-127679

Published: 2019

Journal Articles

Super-Resolution Immunofluorescence Imaging of Platelet Granules

Maurice Swinkels, MSc, BSc, Johan A. Slotman, PhD, Frank W.G. Leebeek, MD PhD, Jan Voorberg, PhD, Ruben Bierings, PhD, Gerard Jansen, MD PhD

Blood (2019) 134 (Supplement_1): 3613.

https://doi.org/10.1182/blood-2019-124353

Published: 2019

NARROW

A master erythroid regulator gets its own GPS

TET1 Modulates DNA Replication in Leukemia Cells Via a Catalytic-Independent Mechanism through Cooperating with KAT8

Leukemogenic Functions of Mutant ASXL1 Are Regulated By CDK-Mediated Phosphorylation

A Novel Composition of Endogenous Metabolic Modulators, AXA4010, Impacts Adhesion, Inflammation and RBC Membrane Deformability in Preclinical Models of Sickle Cell Disease

Multiple Myeloma Epigenetic Programming Prognostic of Outcome Converges with Loci Reprogrammed in Relapsed/Refractory Disease

Innate Immune Signaling Suppresses Acute Leukemia By Modifying MYC Oncogenic Activity

Mechanistic Basis and Efficacy of Targeting β-Catenin-TCF7L2-JMJD6-MYC Axis to Overcome Resistance to BET Inhibitors

Myeloid-Lineage Enhancers Drive Oncogene Synergy and Represent a Novel Therapeutic Target in CSF3R-CEBPA Mutant AML

A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis

Pre-Clinical Efficacy of Co-Treatment with KDM1A (LSD1) Inhibitor and Ruxolitinib or BET Inhibitor Against Post-MPN-sAML Blast Progenitor Cells

Nascent Transcript and Single Cell Rnaseq Analysis Defines the Mechanism of Action of the LSD1 Inhibitor INCB059872 in Myeloid Leukemia

PRMT5 Is a Key Epigenetic Regulator That Promotes Transcriptional Activation in Mantle Cell Lymphoma By Regulating the Lysine Methyltransferase SETD7 and MLL1 Activity

SEL120 - a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial

A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid Leukemia

Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures

Inhibition of LSD1 in Myelodysplastic Syndrome Progenitors Restores Differentiation of CD141 Hi Conventional Dendritic Cells

Myelodysplastic Syndromes-Associated Gene Mutations Lead to Pseudohypoxia Condition and Epigenome Hyper-Methylation in Mouse Genetic Models

Gck Kinase Activity Is Critical for RAS Mutated Myeloma - a Potential Treatment Approach for Targeting Specific Mutations

Novel Therapeutic Rationale for Targeting HDAC1 and PIM2 in Multiple Myeloma

Super-Resolution Immunofluorescence Imaging of Platelet Granules

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only